ArriVent BioPharma AVBP
$10.52 −$0.74 (-6.57%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $10.52 0.00%
Open$11.00
Prev close$11.26
Day range$10.38 – $11.35
Volume1.05M
Market cap$544.13M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$48.38M-26.3% YoY
Net profit-$45.31M-29.5% YoY
Diluted EPS-$0.81+2.4% YoY
Free cash flow-$40.71M-13.7% YoY
Operating cash flow-$40.71M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-49.8%
Return on assets-46.8%
Return on invested capital-53.2%
Current ratio17.64
Liabilities / assets5.7%
Cash & investments$393.22M
Net cash (debt)$393.22M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $48.38M | $52.69M | $46.11M | $177.53M | $38.82M |
| Selling and Admin Expenses | $9.48M | $10.35M | $8.49M | $24.18M | $6.65M |
| -General & Admin Expense | $9.48M | $10.35M | $8.49M | $24.18M | $6.65M |
| Research & Development | $38.90M | $42.34M | $37.62M | $153.35M | $32.18M |
| Operating Profit | -$48.38M | -$52.69M | -$46.11M | -$177.53M | -$38.82M |
| Net Non-Operating Interest Income (Expense) | $3.06M | $2.80M | $2.79M | $11.23M | $3.28M |
| Non-Operating Interest Income | $3.06M | $2.80M | $2.79M | $11.23M | $3.28M |
| Pretax Profit | -$45.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Net Profit | -$45.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Profit from Continuing Operations | -$45.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Net Income to Parent Company | -$45.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Net Income to Common Stockholders | -$45.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Basic EPS | -$0.81 | -$1.05 | -$0.96 | -$4.32 | -$0.78 |
| Diluted EPS | -$0.81 | -$1.05 | -$0.96 | -$4.32 | -$0.78 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $417.09M | $394.72M | $349.30M | $333.17M | $333.17M |
| Total Current Assets | $416.62M | $394.17M | $348.70M | $332.90M | $332.90M |
| Cash and Cash Equivalents & Short-Term Investments | $393.22M | $373.12M | $326.38M | $312.82M | $312.82M |
| -Cash and Cash Equivalents | $113.58M | $154.68M | $62.10M | $45.54M | $45.54M |
| -Short Term Investments | $279.64M | $218.44M | $264.28M | $267.28M | $267.28M |
| Prepaid Assets | $881,000.00 | $1.15M | $1.43M | $186,000.00 | $186,000.00 |
| Other Current Assets | $22.51M | $19.91M | $20.89M | $19.83M | $19.83M |
| Total Non-Current Assets | $474,000.00 | $545,000.00 | $595,000.00 | $272,000.00 | $272,000.00 |
| Net PPE | $302,000.00 | $370,000.00 | $370,000.00 | $13,000.00 | $13,000.00 |
| -Gross PPE | $302,000.00 | $370,000.00 | $370,000.00 | $13,000.00 | $13,000.00 |
| Non-Current Deferred Assets | $38,000.00 | $41,000.00 | $69,000.00 | $69,000.00 | $69,000.00 |
| Other Non-Current Assets | $134,000.00 | $134,000.00 | $156,000.00 | $190,000.00 | $190,000.00 |
| Total Liabilities | $23.61M | $27.88M | $25.32M | $25.95M | $25.95M |
| Total Current Liabilities | $23.61M | $27.84M | $25.00M | $25.95M | $25.95M |
| Payables | $2.62M | $2.22M | $8.73M | $5.93M | $5.93M |
| -Accounts Payable | $2.62M | $2.22M | $8.73M | $5.93M | $5.93M |
| Current Accrued Expenses | $16.52M | $21.64M | $14.24M | $13.45M | $13.45M |
| Short-Term Debt and Capital Lease Obligation | $256,000.00 | $318,000.00 | $99,000.00 | $14,000.00 | $14,000.00 |
| -Current Capital Lease Obligation | $256,000.00 | $318,000.00 | $99,000.00 | $14,000.00 | $14,000.00 |
| Total Non-Current Liabilities | $0.00 | $33,000.00 | $320,000.00 | $0.00 | $0.00 |
| Total Equity | $393.48M | $366.84M | $323.98M | $307.22M | $307.22M |
| Stockholders' Equity | $393.48M | $366.84M | $323.98M | $307.22M | $307.22M |
| Capital Stock | $5,000.00 | $5,000.00 | $5,000.00 | $4,000.00 | $4,000.00 |
| -Common Stock | $5,000.00 | $5,000.00 | $5,000.00 | $4,000.00 | $4,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $932.10M | $864.96M | $772.21M | $711.85M | $711.85M |
| Retained Earnings | -$538.17M | -$497.85M | -$447.96M | -$404.64M | -$404.64M |
| Gains/Losses Not Affecting Retained Earnings | -$466,000.00 | -$267,000.00 | -$270,000.00 | $14,000.00 | $14,000.00 |
| Long Term Debt and Capital Lease Obligation | – | $33,000.00 | $320,000.00 | $0.00 | $0.00 |
| -Long Term Capital Lease Obligation | – | $33,000.00 | $320,000.00 | $0.00 | $0.00 |
| Receivables | – | – | – | $60,000.00 | $60,000.00 |
| -Taxes Receivable | – | – | – | $0.00 | $0.00 |
| -Other Receivables | – | – | – | $60,000.00 | $60,000.00 |
| Investments and Advances | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$40.71M | -$39.58M | -$41.89M | -$160.59M | -$30.66M |
| Net cash flow from continuing operations | -$40.71M | -$39.58M | -$41.89M | -$160.59M | -$30.66M |
| Net Income from Continuing Operations | -$40.31M | -$49.89M | -$43.32M | -$166.31M | -$35.54M |
| Other Non-Cash Items | -$653,000.00 | -$515,000.00 | -$559,000.00 | -$3.03M | – |
| Change in Working Capital | -$6.63M | $4.16M | -$3.50M | -$3.77M | $4.69M |
| -Change in Prepaid Assets | -$2.44M | $1.55M | -$2.56M | -$12.56M | $275,000.00 |
| -Change in Payables and Accrued Expense | -$4.17M | $2.63M | -$1.02M | $8.81M | $4.42M |
| -Change in Other Current Assets | $3,000.00 | $47,000.00 | $37,000.00 | $0.00 | $0.00 |
| -Change in Other Current Liabilities | -$28,000.00 | -$67,000.00 | $47,000.00 | -$21,000.00 | -$5,000.00 |
| Net cash flow from investing | -$60.65M | $46.07M | $3.58M | -$71.23M | -$71.20M |
| Net Cash Flow from Continuing Investing Activities | -$60.65M | $46.07M | $3.58M | -$71.23M | -$71.20M |
| Net Investment Purchase and Sale | -$60.65M | $46.07M | $3.58M | -$71.23M | -$71.20M |
| Financing Cash Flow | $60.26M | $86.09M | $54.87M | $203.06M | $34.73M |
| Net Cash Flow from Continuing Financing Activities | $60.26M | $86.09M | $54.87M | $203.06M | $34.73M |
| Net Common Stock Issuance | $59.66M | $85.24M | $54.72M | $202.63M | $34.66M |
| Proceeds from Stock Option Exercised | $606,000.00 | $853,000.00 | $149,000.00 | $502,000.00 | $84,000.00 |
| Ending Cash Balance | $113.58M | $154.68M | $62.10M | $45.54M | $45.54M |
| Net Change in Cash | -$41.10M | $92.58M | $16.56M | -$28.75M | -$67.13M |
| Beginning Cash Balance | $154.68M | $62.10M | $45.54M | $74.29M | $112.67M |
| Free Cash Flow | -$40.71M | -$39.58M | -$41.89M | -$160.59M | -$30.66M |
| Net Other Financing Charges | – | – | – | -$70,000.00 | -$17,000.00 |
No comments yet — be the first to weigh in on AVBP.
Sign in to join the discussion.